Abstract Library

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4347 Mixed neuroendocrine non-neuroendocrine neoplasm associated with gastric autoimmunity: A clinicopathological analysis of two cases

Introduction: Two cases of mixed neuroendocrine tumour - gastric adenocarcinoma were found in patients with autoimmune atrophic gastritis. Both components expressed synaptophysin, initially suggesting a neuroendocrine tumour diagnosis. However, further examination confirmed the presence of gastric adenocarcinoma of fundic gland type.

Conference:

Presenting Author:

Authors: Huang D, Chen X, Chu J, Ma M,

Keywords: Mixed neuroendocrine tumour, autoimmune atrophic gastritis, gastric adenocarcinoma of fundic gland type,

#4080 Synchronous case of advanced gastric Her-2 + adenocarcinoma and metastatic neuroendocrine neoplasm of unknown origin – A MiNEN case?

Introduction: Gastric adenocarcinoma case treated with capecitabine and trastuzumab. After surgery, a G2 neuroendocrine tumor was found.

Conference:

Presenting Author:

Authors: Jimenez Gordo A, Gomez Raposo C, Garcia-Sancho Tellez L, Salinas Moreno S, Madrid Vallenilla A,

Keywords: MiNEN, clonal selection, citostatic treatment,

#4018 Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine carcinomas and its potential diagnostic value

Introduction: The targeted treatment of DLL3 has attracted attention because of improving the prognosis of small cell lung cancer (SCLC), but the related research on DLL3 in GEP-NEC is relatively rare.

Conference:

Presenting Author:

Authors: Yin L, Jiang K, Zhao X, Hu Y, Lu M,

Keywords: DLL3, gastroenteropancreatic neuroendocrine carcinoma, targeted therapy, diagonsis,

#2855 Whole Exome Sequencing Reveals the Monoclonal Origin of Gastric Mixed Adenoneuroendocrine Carcinomas

Introduction: Gastric mixed adenoneuroendocrine carcinomas (g-MANECs) are rare neoplasms consisting of adenocarcinoma and neuroendocrine neoplastic components. G-MANECs show more malignant characteristics than gastric adenocarcinomas, while molecular mechanisms underlying the co-existence of the two components remains unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Yan S, Chen X, Zhang R, Song L, Yin F,

Keywords: whole exome sequencing, mixed adenoneuroendocrine carcinoma, Stomach, Evolution,